Mitochondrial Biomarker Predicts Type 2 Diabetes Hazard
The review protected in this summary was released on researchsquare.com as a preprint and has not still been peer reviewed.
Crucial Takeaway
-
ATPase inhibitory factor 1 (IF1) has been hypothesized as a biomarker of mitochondrial strength metabolic process in which higher degrees are associated with safety versus insulin resistance. Between people with prediabetes who had lower plasma ranges of IF1, the amount of incident sort 2 diabetic issues was noticeably increased, independently of age, intercourse, and fasting plasma glucose ranges.
Why This Matters
-
The authors say that this the to start with study in which an inverse connection was located concerning plasma IF1 amount and a person’s hazard of producing variety 2 diabetic issues.
-
Dysfunction in a mitochondrial energy pathway might add to insulin resistance. Reduced plasma stages of IF1 show up to flag this problem and replicate organic processes not captured by regular chance variables for diabetic issues or bioclinical variables and existing biomarkers of glycemic manage.
-
Larger concentrations of plasma IF1 could show optimal mitochondrial energetics.
Review Style and design
-
The 5-12 months, potential, observational IT-DIAB analyze included 307 people with prediabetes. The research was created to identify new biomarkers of form 2 diabetic issues risk in men and women prediabetes (fasting plasma glucose of ≥110 and <126 mg/dL 6.0–7.0 mmol/L).
-
The primary outcome was the association between baseline plasma IF1 levels and subsequent development of type 2 diabetes during a median 4.9-year follow-up.
-
The researchers also ran cross-sectional analyses of data collected in two independent, interventional studies.
Key Results
-
During follow-up, 115 of the IT-DIAB participants (37%) developed type 2 diabetes.
-
Among those who developed type 2 diabetes, baseline IF1 levels were lower compared to those who did not: 537 ng/mL vs 621 ng/mL (P = .010).
-
After adjustment for age, sex, and fasting plasma glucose level, higher baseline plasma levels of IF1 were significantly and negatively linked with development of type 2 diabetes, with a hazard ratio of 0.76 for each standard deviation increase in baseline IF1 (P = .012). Further adjustment for either baseline levels of triglycerides or A1c made the association less robust and nonsignificant, although the directionality of effect was the same.
-
In the two cross-sectional studies as well as in the primary cohort, plasma levels of IF1 were negatively associated with body mass index and plasma triglyceride levels, and there were positive correlations with plasma levels of high-density lipoprotein cholesterol and apolipoprotein A-I.
Limitations
-
The relatively small size of the prospective cohort limits the study’s statistical power. The authors suggest that prospective studies with larger cohorts be conducted.
-
The study design did not allow determination of the optimal level of plasma IF1 that was associated with protection against the development of type 2 diabetes.
Disclosures
This is a summary of a preprint research study, “Plasma Level of ATPase Inhibitory Factor 1 (IF1) Is Associated With Type 2 Diabetes Risk in Humans: A Prospective Cohort Study,” by researchers primarily at the University of Toulouse, France, published on Research Square, and brought to you by Medscape. The study has not yet been peer reviewed. The full text of the study can be found on researchsquare.com.
For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.